Search

Contributor:

Ehsan Rahimy, MD

AAO Late Breaker: IRIS Registry Data on GA

COVID-19: Telemedicine in Retina

John Kitchens, MD; S.K. Steven Houston III, MD; John B. Miller, MD; and Ehsan Rahimy, MD

Submacular Hemorrhage

Submacular Hemorrhage

COVID-19: Telemedicine in Retina

COVID-19: Telemedicine in Retina

Ehsan Rahimy, MD, John B. Miller, MD, John Kitchens, MD, S. K. Steven Houston III, MD

Reinjection Criteria

Reinjection Criteria

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

Patient Selection for EYP-1901

Patient Selection for EYP-1901

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

2023 VBS Lifetime Achievement Award

2023 VBS Lifetime Achievement Award

Ehsan Rahimy, MD, and Allen C. Ho, MD

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901?

How May Tolerance for Subretinal Fluid Change Given Sustained-Release EYP-1901?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

How Can a Multi-MOA Approach Benefit the Management of Wet AMD?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME?

What Evidence Makes EYP-1901 a Promising Treatment for Wet AMD and DME?

Sophie Bakri, MD; Ehsan Rahimy, MD; and Lejla Vajzovic, MD

St<strike>ep</strike>upid Edits in a Neovascular AMD Patient

Stepupid Edits in a Neovascular AMD Patient

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

Switching From Bevacizumab to Aflibercept 8 mg in a Patient With Neovascular AMD

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

Neovascular AMD (PCV Variant) Patient Switched to Two Different Next-generation Therapies

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

Switching from Bevacizumab to Aflibercept 8 mg in a Neovascular AMD Patient After Handoff from a Colleague

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

Conversion to Neovascular AMD in a Geographic Atrophy Patient With a 2-Year Treatment History

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

Switching From Aflibercept 2 mg to Faricimab in a Patient With Newly Diagnosed Neovascular AMD and Worsening Pigment Epithelium Detachment

David Miller, MD; Ehsan Rahimy, MD; and Esther Kim, MD

Case Review: Pediatric Ocular Toxoplasmosis

Sila Bal, MD, MPH; and Ehsan Rahimy, MD

Wet AMD and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

DME, DR, and Next-Generation Therapies

David Miller, MD; Esther Kim, MD; and Ehsan Rahimy, MD

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

David Lally, MD; and Ehsan Rahimy, MD

AAO Late Breaker: IRIS Registry Data on GA

Ehsan Rahimy, MD